摘要
目的:观察奥沙利铂联合胸腺肽治疗肺癌合并恶性胸腔积液的临床疗效。方法:选取已确诊为肺癌合并恶性胸腔积液的60例患者作为本次研究对象。按照病历单双号分组,单号为对照组给予常规化疗,双号为观察组在对照组的基础上给予奥沙利铂联合胸腺肽治疗,比较两组患者的胸水吸收率及不良反应发生率。结果:两组患者治疗后,观察组的胸水吸收率为73.33%,高于对照组的20.00%(P<0.05);不良反应发生率明显小于对照组(P<0.05)。结论:在常规化疗基础上,采用奥沙利铂联合胸腺肽治疗肺癌合并恶性胸腔积液的临床疗效优于单纯常规化疗疗效。
Objective： To investigate clinical effects of Oxaliplatin combined with Thymosin in treatment of lung cancer complicated with malignant pleural effusion. Methods： 60 cases with lung cancer complicated with malignant pleural effusion were selected as study objects. They were divided into two groups according to medical record number. The patients with odd numbers were set as the control group and were given routine chemotherapy,while those the even numbers were used as the observation group and given Oxaliplatin combined with Thymosin on the basis of that of the control group. The pleural effusion absorption rates and adverse reaction rates of the two groups were compared. Results： After the treatment,the pleural effusion absorption rate of the observation group（ 73.33%）was higher than that of the control group（ 20.00%,P〈0. 05）,but the adverse reaction rate was significantly higher than that of the control group（ P〈0.05）. Conclusions： Oxaliplatin combined with Thymosin based on routine chemotherapy in the treatment of lung cancer complicated with malignant pleural effusion is more effective than single routine chemotherapy.
作者
巩天晓
王海莉
王豪勋
韩娜
张中冕
GONG Tianxiao;WANG Haili;WANG Haoxun;HAN Na;ZHANG Zhongmian(The Second Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, 450014, China)
出处
《中国民康医学》
2018年第7期19-20,25,共3页
Medical Journal of Chinese People’s Health
关键词
奥沙利铂
胸腺肽
肺癌合并恶性胸腔积液
临床疗效
Oxaliplatin
Thymosin
Lung cancer complicated with malignant pleural effusion
Clinical effect
